Sanhuang Kangqiu Granules Veterinary Grade API is supplied as a granulated multi-component botanical active pharmaceutical ingredient for further processing into tablets, injections, capsules, powders, granules, premixes, and solutions. The commercial designation is Sanhuang Kangqiu Granules Veterinary Grade API; the current manufacturer does not assign a separate model number on the public technical data sheet. Batch traceability is maintained through lot numbers and the certificate of analysis identifier, which should be referenced on all purchase documents. Because the material is a multi-component botanical granule rather than a single chemical entity, batch-to-batch behavior depends on the ratio of extractable marker compounds, particle size distribution, residual moisture, and microbial burden. The granulated format is designed to reduce airborne dust and improve flow into tablet press dies and capsule filling systems compared with micronized spray-dried botanical powders. Published data for this specific configuration are limited; therefore, process development decisions must be based on batch-specific HPLC marker profiles and particle size data generated by the receiving manufacturer.

Release specifications should cover appearance, identification, loss on drying, particle size distribution, heavy metals, arsenic, and microbial limits. Identification by HPLC fingerprint is more informative than a single marker assay because the relative peak areas of the constituent compounds affect dissolution and processing. Loss on drying is critical: granulated botanical materials with moisture above 8.0% tend to cake in bulk bags and produce variable tablet hardness, while over-dried material below 3.0% generates fines and segregates in intermediate bulk containers. The certificate of analysis should state the drying method and temperature; loss-on-drying data alone are not sufficient for scale-up. Microbial enumeration and specified pathogens should be tested according to the relevant pharmacopoeial general chapters. For oral dosage forms, a total aerobic microbial count above 10³ CFU/g is generally regarded as a process risk for wet granulation; it is not a release limit for this API. For injectable manufacturing, the base API is not sterilized and requires additional bioburden reduction.

What Processing Windows Apply to Each Finished Dosage Form?

For tableting, the receiving manufacturer should characterize flowability and compressibility before setting press parameters. Granules with a Hausner ratio below 1.25 and fines below 20% w/w through a 75 µm sieve generally feed uniformly through a rotary tablet press equipped with a forced feeder. Direct compression is rarely applied to botanical APIs without excipient adjustment; dry granulation or roller compaction may be used when the as-received granule size distribution is broader than desired. For capsule filling, dosator and tamping-pin machines respond to bulk density and particle size; a D50 between 150 µm and 500 µm is a practical starting range, but segregation can occur if the D90/D10 ratio exceeds 3.0.

In premix manufacturing, the granulated API is combined with mineral or grain carriers in ribbon blenders or double-cone tumble blenders. The main batch uniformity risk is segregation of fine particles when the carrier particle size is much larger than the API granule size. The use of a granulated rather than micronized API reduces this risk because the densified granules have a higher bulk density and lower dusting tendency. For powders and granules intended for oral administration via feed or drinking water, the API should be evaluated for dispersibility in the final vehicle. Poorly dispersible granules may require pre-wetting with a small amount of feed-grade surfactant before addition to water tanks. In solutions, the pH of the vehicle and the presence of chelating agents or metal ions can alter marker compound stability; stainless steel 316L mixing vessels are preferred over carbon steel to reduce iron-catalyzed degradation.

Particle Size Distribution, Residual Moisture, and Heavy-Metal Boundaries

Particle size distribution is determined by sieve analysis using ISO 3310-1:2016 test sieves or by laser diffraction using ISO 13320:2020. For granulated botanical APIs, sieve analysis is usually sufficient for tablet and premix applications because the relevant fractions are above 75 µm. Laser diffraction is preferred when a high proportion of fines is suspected or when the granule surface is fragile. Residual moisture should be measured by a validated loss-on-drying or Karl Fischer method. The botanical matrix is hygroscopic; storage above 60% relative humidity may increase moisture uptake and initiate microbial growth. Heavy metal limits should be specified for lead, cadmium, arsenic, and mercury, with methods aligned to the Chinese Veterinary Pharmacopoeia or an equivalent pharmacopoeial general chapter. The manufacturer should provide a worst-case elemental impurity statement for the botanical raw materials because heavy metal content can vary with geographic origin and soil conditions. An elemental impurity risk assessment aligned with ICH Q3D may be requested for export applications, even though the veterinary scope does not always mandate it.

Operational Differences That Affect Tablet, Premix, and Cleaning Performance

Three operational differences separate this material from micronized single-entity veterinary APIs. First, the API is a multi-component botanical granule; therefore, the certificate of analysis should report a chromatographic fingerprint or multiple marker peaks rather than a single potency value. Process adjustments based on one marker alone may fail to capture changes in the relative proportion of other constituents. Second, the granulated format reduces dust generation during dispensing and charging. In multi-product facilities, this reduces the airborne deposition that can trigger cleaning validation failures; however, the product still requires dedicated or validated multi-use equipment because of its coloring and resinous constituents. Third, the material is intended for further manufacturing, not for direct administration. It is not a finished veterinary medicinal product, and it does not carry a route-specific marketing authorization. For tableting, the granulated API may require lower levels of dry binder than a micronized powder, but its natural variation in extractable matter means that hardness and disintegration time must be confirmed on each batch. No therapeutic equivalence claim can be inferred from chromatographic similarity alone; comparative field efficacy studies are required for regulatory substitution.

For injectable manufacturing, the base granulated API is not sterile, not depyrogenated, and not necessarily free of subvisible particulates. The receiving manufacturer must add a dedicated clarification and bioburden reduction train. A sterilizing-grade filter with a nominal rating of 0.22 µm is not sufficient if the feed stream contains high particulate load; pre-filtration through depth filters or 0.45 µm membranes is commonly required. Membrane compatibility studies are mandatory because polyphenolic constituents in botanical APIs can adsorb to nylon and, in some cases, to hydrophobic polyvinylidene fluoride membranes. Regenerated cellulose or polyethersulfone membranes should be evaluated using product-specific adsorption studies. The bacterial endotoxin limit for the finished injectable veterinary product must be derived from the target species, route, and dose; the base API specification should therefore include a bacterial endotoxin method and limit, typically by kinetic chromogenic or gel clot assay. If the manufacturer cannot provide an endotoxin limit for the granulated base material, the injection claim is not supported by the batch documentation. Terminal sterilization using moist heat at 121 °C for 15 minutes may degrade thermolabile marker constituents; therefore, aseptic filtration after cold clarification is preferred for heat-sensitive formulations.

When the Same API Is Specified for Oral Solutions and Injectable Preparations

The dual use of a single API across oral solutions and injectable preparations places divergent demands on the release specification. An oral solution can tolerate higher bioburden and endotoxin loads because the gastrointestinal tract is a barrier; an injectable preparation cannot. Therefore, a batch accepted for oral solution manufacture is not automatically acceptable for parenteral manufacture. The receiving manufacturer must segregate incoming lots by intended route and apply route-specific microbial, endotoxin, and particulate controls. For oral solutions, a 0.45 µm clarification filter may be sufficient; for injectables, the filtration train must be designed to achieve sterility assurance. The API’s water-soluble fraction, pH shift, and precipitation behavior in aqueous vehicles must be characterized before route selection. If the marker compounds are poorly water-soluble, oral solutions may require co-solvents or micellar systems, while injectable formulations may require additional solubilization strategies such as cyclodextrin complexation or pH adjustment, provided the active constituents are stable.

Which Regulatory Documentation Must Accompany a Multi-Component Veterinary API?

The following documents should be obtained and reviewed before process validation: certificate of analysis, safety data sheet, current GMP certificate or audit report, batch-specific HPLC fingerprint, residual solvent declaration, elemental impurity statement, and TSE/BSE declaration. For products intended for the European market, compliance with Regulation (EU) 2019/6 for veterinary medicinal products applies to the finished product; the API must be manufactured under an appropriate quality system and the supply chain verified. For products distributed in China, the Chinese Veterinary Pharmacopoeia general chapters govern relevant test methods and limits. The API is not intended for human use and must be handled in segregated veterinary-only production areas. If the receiving site also manufactures human medicinal products, cleaning validation should include marker compounds specific to this botanical matrix to prevent cross-contamination.

Stability data for the granulated API should include at least open and closed container conditions. Because botanical extracts can darken over time, appearance alone is not a stability-indicating parameter; HPLC marker peak area ratio and loss on drying are more objective. The retest period assigned by the manufacturer should be based on real-time stability batches; accelerated data at 40 °C/75% RH are supportive but do not replace real-time data for a botanical matrix. The API should be stored away from strong light and moisture. Each container should be sealed after use, and partially used drums should be returned to controlled storage immediately. For premix operations, the API’s bulk density affects the accuracy of volumetric dosing; weigh-cells on mixers should be calibrated with the actual product rather than a surrogate powder.

Cleaning Validation for Resinous Botanical Granules in Multi-Product Plants

Cleaning validation for this API is complicated by its intense color and resinous constituents. Visual cleanliness alone may be acceptable as a preliminary check, but swab samples should be analyzed for a specific marker compound by HPLC. Carryover limits should be based on toxicological or pharmacopoeial limits and the maximum daily dose of the next product. In a multi-product veterinary facility, the use of closed transfer systems and disposable liners reduces cross-contamination risk. If the granulated API is charged manually, operators should use local exhaust ventilation and appropriate respiratory protection because the dust may contain sensitizing plant proteins. Equipment contact surfaces should be 316L stainless steel or validated polymeric materials; prolonged contact with mild steel can promote color changes in the botanical extracts. The cleaning process should be qualified using worst-case holding times, because dried resin films are more difficult to remove than freshly deposited powder.

During scale-up, the receiving manufacturer should not assume that laboratory powder flow measurements predict production behavior. Small-scale angle-of-repose tests may underestimate bridging tendencies in large static hoppers. The API should be evaluated in the actual production hopper or a pilot-scale simulant with the same outlet geometry. For tablet compression, the first production runs should use a rotary press with force feeder speed adjustable across a range of 20–80 rpm to detect segregation. For capsule operations, empty capsule shell moisture and the hygroscopic nature of the granulated botanical matrix interact; relative humidity above 45% in the filling suite may cause sticky granule surfaces and increase reject rates. Therefore, environmental controls for direct transfer and weighing should be established before large batches are committed.